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In Brief
Pericytes are unique support cells of the
microvasculature that are able to
contract. However, this capacity is
altered in leaky tumor vessels.
Johansson-Percival et al. developed a
cytokine therapy that restores
contractility of intratumoral pericytes and
vessel integrity. These effects are specific
to the vascular bed and enhance anti-
tumor therapies.
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Normalization of the tumor vasculature is an
emerging concept shown to improve anti-cancer
therapy. However, there are currently no clinical in-
terventions that effect long-lasting normalization.
Here, we have developed a strategy for normalization
by specific intratumoral delivery of LIGHT/TNFSF14.
Importantly, normalization occurs by induced
expression of contractile markers in intratumoral
pericytes, which in turn re-establishes tight peri-
cyte-vessel alignment. Restoring vessel integrity im-
proves tumor perfusion and acts as adjuvant to
chemo- and immunotherapy. Mechanistically, intra-
tumoral LIGHT induces pericyte differentiation and
normalization via Rho kinase signaling. Minute
amounts of LIGHT act in a paracrine fashion to trigger
an amplifying cascade involving transforming growth
factor b (TGF-b) from peri-vascular macrophages.
That these effects can be reproduced by adoptive
transfer of LIGHT-stimulated macrophages alone
demonstrates their central role in regulating pericyte
differentiation. Our findings highlight a crucial role of
pericyte contractile properties in vascular normaliza-
tion, effected by macrophage signaling, thus
providing so far unexplored anti-cancer opportu-
nities.INTRODUCTION
The tumor microenvironment harbors a network of stromal cells
and growth factors that actively promote cancer progression
and immune suppression. Chronic pro-angiogenic signaling be-
tween tumor-associated immune cells and the vasculature re-
duces tumor perfusion and ultimately drug access (Coussens
et al., 2013). In contrast, specific modulation or reprogramming
of stromal signaling networks can lead to tumor vessel normali-
zation and increased responses to anti-cancer chemo or im-
mune therapies (De Palma et al., 2008; Johansson et al.,
2012b; Rolny et al., 2011). Normalized tumor vasculature collec-Cell Reptively describes more organized, homogeneous, and better
perfused vessels in contrast to the chaotic vasculature of un-
treated solid tumors (Carmeliet and Jain, 2011; Johansson
et al., 2014). However, vessel normalization remains a highly
descriptive entity that refers to parameters such as quantitative
mural cell or pericyte coverage of endothelial cells, basement
membrane composition, and vessel permeability (Goel et al.,
2011). Most current genetic and pharmacological normalization
strategies focus on endothelial cells (Jain, 2014; Magrini et al.,
2014; Rolny et al., 2011). However, we and others have demon-
strated a crucial role for pericytes in the normalization process
that, for instance, involves platelet-derived growth factor B
(PDGFB)/PDGFB receptor b (PDGFRb) interactions (Abramsson
et al., 2003; di Tomaso et al., 2009) or modulation of the regulator
of G protein signaling 5 (RGS5) (Hamzah et al., 2008a). Induction
of a more mature and normal tumor vasculature by manipulating
either endothelial cells or pericytes is consistent with the notion
of reciprocal interactions between all vascular components
(Armulik et al., 2005). Pericytes are unique mural cells of the
microvasculature that share with vascular smooth muscle cells
(vSMC) the ability to contract and regulate endothelial prolifera-
tion (Gaengel et al., 2009; Rucker et al., 2000). However, this ca-
pacity is altered or lost in intratumoral pericytes. Indeed, weak or
absent expression of contractile proteins in human tumors is
associated with aggressive growth, metastatic dissemination,
and poor survival (Islam et al., 2004). The role of pericyte con-
tractile phenotype in vascular normalization has so far not
been explored.
LIGHT, an acronym for homologous to lymphotoxins, exhibits
inducible expression, and competes with HSV glycoprotein D for
HVEM, a receptor expressed by T lymphocytes, or TNFSF14, is a
transmembrane glycoprotein of the tumor-necrosis factor (TNF)
super family. LIGHT interacts with herpes virus entry mediator
(HVEM) and lymphotoxin beta receptor (LTbR). HVEM is pre-
dominantly, but not exclusively, expressed on immune cells,
including monocytes/macrophages, and a co-stimulatory acti-
vator of T cells (Morel et al., 2000); LTbR is constitutive on
most cell types but absent on T and B lymphocytes that produce
LTbR ligands (Force et al., 1995). Stromal cells such as endothe-
lial cells, fibroblasts, and vSMC signal through both HVEM and
LTbR (Chang et al., 2005; Wei et al., 2006). Thus, LIGHT is a
potent immune co-stimulator that is also associated with tissue
remodeling and wound healing (Doherty et al., 2011; Petreacaorts 13, 2687–2698, December 29, 2015 ª2015 The Authors 2687
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et al., 2012). This dual capacity makes LIGHT an attractive cyto-
kine to explore in cancer (Tamada et al., 2000). Indeed, ectopic
expression of LIGHT in tumors facilitates T cell-dependent tumor
rejection, an effect mediated in part by changes in the tumor
stroma (Yu et al., 2004). Specifically, LIGHT overexpression in
cancer cells upregulates chemokines and adhesion molecules
in the tumor environment concomitant with recruitment and
priming of naive anti-tumor T cells. While LIGHT-mediated anti-
tumor immune effects have been well established (Fan et al.,
2006; Kanodia et al., 2010; Zhang et al., 2008; Zou et al.,
2012), it is less clear which stromal cells are activated by LIGHT
and whether modulation of the vascular barrier contributes to
anti-tumor immunity. Furthermore, experimental delivery of
LIGHT into solid tumors is so far limited to direct injection of
adenoviral constructs or ectopic expression in mesenchymal
stem cells that spontaneously home into tumors (Yu et al.,
2007; Zou et al., 2012).
Here, we developed an approach that employs peptide-tar-
geting to specifically deliver physiological amounts of LIGHT
into the tumor environment of spontaneously arising pancreatic
neuroendocrine and orthotopic breast cancers. Surprisingly,
LIGHT has profound direct and indirect effects on the angiogenic
vasculature that simultaneously increases tumor perfusion and
anti-tumor effector cell penetration. Our data also demonstrate
an exquisite interplay between tumor resident peri-vascular
macrophages and the vascular bed that can be exploited to
reverse angiogenesis and restore vessel function.
RESULTS
Intratumoral Low Dose LIGHT Acts as Adjuvant to
Promote Anti-tumor Immunity
LIGHT is a proinflammatory factor that induces expression of cy-
tokines and adhesion molecules on vascular endothelial cells
in vitro (Chang et al., 2005). To specifically target LIGHT into solid
tumors, a recombinant LIGHT-RGR peptide fusion compound
was produced (Figure S1A). Intravenously (i.v.) injected RGR
peptide (CRGRRST) binds to 60% of angiogenic but not
normal vessels (Figure S1B) and has been shown to deliverFigure 1. LIGHT-RGR Activates the Tumor Vasculature and Facilitates
(A) Biotinylated LIGHT or LIGHT-RGR (LR) were injected i.v. into tumor-bearing RIP
assessed by histology. Arrows point to LIGHT-RGR attached to vessels. Sca
are shown.
(B) Specific activation of tumor endothelial cells in untreated groups (Untr), or fo
assessed by ICAM-1 immunohistochemistry. Intratumoral ICAM-1 staining was
groups, Student’s t test. Scale bar, 100 mm. Representative images from three in
(C) Immunohistochemical analysis of tumor infiltrating CD8+ T cells in untreated
transfer (AdT) of ex vivo-activated TagTCR8 cells only, or a combination of LIGH
groups; n = 4–6 mice. *p < 0.05 compared to all experimental groups, Student’s
periments are shown.
(D) Schematic representation of AdT (end point study, 30 weeks) or vaccinatio
treated ± bi-weekly LR or LIGHT i.v. injections.
(E) Survival of untreated mice (Untr; n = 8 mice), mice treated with LIGHT (n = 6),
(n = 15) was determined at a pre-defined end point (30 weeks). *p = 0.038 (Pear
(F) Kaplan-Meier survival analysis of untreatedmice (n = 10), anti-Tag vaccinatedm
*p = 0.006 vaccine + LR compared to vaccine alone, *p = 0.0003 vaccine + LR c
(G) The majority of tumors isolated from LR + AdT mice appear macroscopically
Data are presented as mean ± SD.
See also Figure S1 and Supplemental Experimental Procedures for details.
Cell Repfusion compounds into pancreatic neuroendocrine tumors of
rat insulin gene promoter-large SV40 T antigen (RIP-Tag) mice
(Hamzah et al., 2008b, 2009; Johansson et al., 2012a; Joyce
et al., 2003). Recombinant LIGHT-RGR, in contrast to unconju-
gated LIGHT, homes into RIP1-Tag5 tumors and is specifically
retained on blood vessels (Figure 1A). To assess potential
vascular effects of LIGHT-RGR in vivo, tumor bearing RIP1-
Tag5mice were treated for 2 weeks with bi-weekly i.v. injections.
A dose-response analysis revealed that a very low dose of
LIGHT-RGR (0.2 ng or 6 ng/kg body weight), but not unconju-
gated LIGHT, is sufficient to induce expression of ICAM-1 on tu-
mor endothelial cells (Figure 1B). This low dose is insufficient to
stimulate spontaneous anti-tumor immunity as assessed by the
number of infiltrating CD8+ T cells (Figure 1C). However,
combining low dose LIGHT-RGR treatment with adoptive trans-
fers of ex vivo-activated anti-tumor CD8+ effector cells, which
normally do not extravasate into the tumor tissue (Ganss et al.,
2002), significantly increases tumor infiltration (Figure 1C). This
result demonstrates that LIGHT-RGR pre-treatment renders tu-
mors permissive for T cell infiltration.
RIP1-Tag5 mice develop tumors over a period of 20 weeks
and, without treatment, die between 26 to 32 weeks of age
(Ganss et al., 2002). To assess the potency of LIGHT-RGR as
an adjuvant, 23-week-old tumor-bearing RIP1-Tag5 mice were
treated with LIGHT-RGR and adoptive transfers or anti-tumor
vaccination (Figure 1D). For adoptive transfer experiments,
mice were treated for a total of 8 weeks; survival was recorded
at the pre-set endpoint of 30 weeks. Mice undergoing combina-
tion treatment are 5.5 times more likely (odds ratio, p = 0.038,
Pearson’s chi-square test, p = 0.045 Fisher’s exact test) to sur-
vive until week 30 than groups treated with adoptive transfers
only (Figures 1E and S1C). Similarly, therapeutic anti-Tag vacci-
nation is ineffective in RIP1-Tag5 mice (Garbi et al., 2004) (Fig-
ure1F). However, combinationof LIGHT-RGRandvaccine signif-
icantly prolongs survival of tumor-bearing mice when compared
to vaccinegroupsor LIGHTcombinedwith vaccine (p=0.006, p=
0.04, respectively, Figure 1F). Interestingly, themajority of tumors
from LIGHT-RGR/adoptive transfer combination treatment
groups at 30weeks are typically ‘‘white’’ in appearance indicativeT Cell Access
1-Tag5mice. LIGHT or LIGHT-RGR binding to tumor vessels (CD31+, red) was
le bar, 50 mm. Representative images from three independent experiments
llowing a short-term (2 weeks) treatment regimen with 0.2 ng LIGHT or LR, as
quantified in all groups; n = 3–7 mice. *p < 0.05 compared to all experimental
dependent experiments are shown.
tumors, LIGHT, LR-treated tumors, or tumors from mice treated with adoptive
T or LR and adoptive transfers. Intratumoral CD8+ T cells were quantified in all
t test. Scale bar, 50 mm. Representative images from three independent ex-
n (survival study) treatment regimens in RIP1-Tag5 mice. Both groups were
LR (n = 17), AdT only (n = 12), or mice treated with LR in combination with AdT
son’s chi-square test) or p = 0.045 (Fisher’s exact test), AdT versus AdT + LR.
ice (n = 7), vaccination combined with LIGHT (n = 8), or LIGHT-RGR (LR, n = 8).
ompared to untreated, *p = 0.04 vaccine + LIGHT.
pale in contrast to more hemorrhagic tumors in untreated and AdT groups.
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Figure 2. LIGHT-RGR Treatment Normalizes
Tumor Vessels
Vascular changes in RIP1-Tag5 tumors, analyzed
after 2 weeks of treatment with 0.2 ng LIGHT or
LIGHT-RGR (LR) in comparison to untreated tu-
mors (Untr). Representative images from at least
three independent experiments are shown. *p <
0.05, **p < 0.01. Student’s t test. Data are pre-
sented as mean ± SD.
(A) Representative vascular staining (CD31+) in
untreated, LIGHT and LR treatment groups and
indication of vessel size (two to three representa-
tive vessels per group are demarcated). Scale bar,
50 mm.
(B) Quantification of mean vessel lengths (left) and
vessel diameters (right) in all treatment groups, n =
6 mice, 100–150 vessels/group were assessed.
(C) Quantification of overall vascularity (total CD31+
vessels) in all treatment groups.
(D) Endothelial (CD31+) coverage by aSMA+ peri-
cytes and quantification of pericyte protrusion into
parenchyma. Bars indicate broad/fuzzy appear-
ance in contrast to closely aligned vascular com-
ponents; n = 4–10 mice. Scale bar, 50 mm.
(E) Endothelial (CD31+) coverage by NG2+ peri-
cytes and quantification of pericyte protrusion into
parenchyma. Bars indicate broad/fuzzy appear-
ance in contrast to closely aligned vascular com-
ponents; n = 4–10 mice. Scale bar, 50 mm.
(F) Association of collagen IV (Col IV) with the
vascular bed (CD31+/aSMA+) and quantification of
total tumor Col IV content. Bars indicate broad/
fuzzy appearance in contrast to closely aligned
vascular components; n = 4–10 mice. Scale bar,
50 mm.
See also Figure S2.of reduced hemorrhaging and tumor vessel remodeling in the
context of a Th1 immune response (Figure 1G).
Intratumoral LIGHT Normalizes the Vasculature
and Increases Tumor Perfusion
The ‘‘white’’ tumor appearance prompted us to explore a poten-
tial role of LIGHT-RGR in vessel remodeling. Tumor bearing
27-week-old RIP1-Tag5 mice were treated for 2 weeks with bi-
weekly i.v. LIGHT-RGR injections. In treated tumors, CD31+ ves-
sels are smaller with decreased lengths and diameters (Figures
2A and 2B). Importantly, the shift in vessel caliber is not associ-
ated with an overall change in vascularity demonstrating that
LIGHT-RGR treatment does not deplete tumor vessels (Fig-
ure 2C). To assess pericyte coverage, tumors were co-stained
with the vessel marker CD31 and the pericyte markers aSMA
and NG2. In RIP-Tag tumors, aSMA+ cells are almost exclusively
located around blood vessels and also positive for NG2, thus
representing aSMA+ pericytes (Figures S2A–S2C). Furthermore,
CD31+ endothelial cells and NG2+ pericytes express both HEVM
and LTbR, immune cells predominantly express HVEM, whereas
expression of the receptors in epithelial cells is negligible (Fig-
ures S2D and S2E). Upon LIGHT-RGR treatment, aSMA or2690 Cell Reports 13, 2687–2698, December 29, 2015 ª2015 The AuNG2 vessel coverage remains unchanged (Figures S2F and
S2G). However, protrusion of aSMA+ or NG2+ pericyte sheaths
away from endothelial cells into the tumor parenchyma, a hall-
mark of angiogenic vessels (Morikawa et al., 2002; Xian et al.,
2006), is significantly diminished (Figures 2D and 2E). Similarly,
the typically aberrant thickness of the vascular basement mem-
brane (Baluk et al., 2003), which connects pericytes and endo-
thelial cells, is reduced upon LIGHT-RGR treatment as assessed
by collagen IV staining (Figure 2F). These morphological
changes are consistent with features of a normalized vasculature
(Goel et al., 2011). Importantly, LIGHT-induced vascular
changes significantly reduce dextran extravasation into the inter-
stitium, a marker for vascular leakiness (Figure 3A). This corre-
lates with enhanced tumor perfusion as inferred by increased
FITC-lectin binding to tumor vessels (Figure 3B). Consistently,
LIGHT-RGR treatment increases the efficacy of the cytotoxic
drug cyclophosphamide when administered continuously
through the drinking water following an 8-week metronomic
treatment regimen (Pietras and Hanahan, 2005). Specifically,
combination treatment induces tumor cell apoptosis at higher
frequency (2-fold increase, Figure 3C) and decreases tumor pro-
gression compared to cyclophosphamide and LIGHT-RGRthors
Figure 3. LIGHT-RGR Treatment Improves
Tumor Perfusion and Drug Delivery
(A) Histology image of intratumoral dextran (red)
following injection with 70 kDa Texas Red dextran
and quantification of extravasated dextran as
surrogate marker for vascular leakiness in un-
treated (Untr) and LIGHT-RGR (LR)-treated tu-
mors. Representative images from at least three
independent experiments are shown. Data are
presented as mean ± SD. n = 4–7 mice, *p < 0.05,
Student’s t test. Scale bar, 100 mm.
(B) Overlay of CD31+ vessels with FITC-lectin de-
lineates perfused (yellow) and non-perfused (red)
tumor vessels in untreated and LR-treated groups.
Representative images from at least three inde-
pendent experiments are shown. Data are pre-
sented as mean ± SD. n = 4–7 mice, *p < 0.05,
Student’s t test. Scale bar, 50 mm.
(C) Intratumoral apoptosis (TUNEL, green) in un-
treated RIP1-Tag5 mice and after long term
treatment (8 weeks) with cyclophosphamide
(Cyclo), LR, or a combination of Cyclo + LR.
Quantification of TUNEL+ cells in relation to total
cells (DAPI+ nuclei). Representative images from
at least three independent experiments are
shown. Data are presented as mean ± SD. n = 5–7
mice. **p % 0.01, Student’s t test. Scale bar,
100 mm.
(D) Quantification of mean tumor size in untreated
and treated RIP1-Tag5 mice (age at endpoint:
30 weeks), n = 10–12 mice. *p% 0.04, Student’s t
test.
(E) Kaplan-Meier survival analysis of untreated
RIP1-Tag5 mice and after treatment with Cyclo,
LR, or a combination of Cyclo + LR (n = 8 for all
groups). *p = 0.05, Cyclo + LR compared to Cyclo.
*p = 0.01, Cyclo + LR compared to all other
groups.
See also Figure S3.alone, or untreated controls (Figure 3D). This translates into a sig-
nificant survival advantage in the combination treatment group
as compared to untreated or cyclophosphamide groups (Fig-
ure 3E, p = 0.01). Since insulinomas are resistant to chemo-
therapy, this finding is remarkable and indicates that LIGHT-
RGR treatment substantially increases tumor perfusion and
drug access. Importantly, after 8 weeks of continuous treatment,
tumor vessels and margins remain intact, thus demonstrating
that long-term treatment does not promote vessel death or tu-
mor invasiveness (Figures S3A and S3B).
LIGHT Reprograms Pericyte Phenotype
Molecular mechanisms of vascular normalization are poorly
defined. Surprisingly, gene expression profiling of untreated andCell Reports 13, 2687–2698, DeLIGHT-RGR-treated tumors, which most
significantly differ in tumor perfusion, re-
vealed a prominent gene signature of
vSMC differentiation markers as well as
transforming growth factor b (TGF-b) that
is a potent inducer of pericyte maturation
(Hirschi et al., 1998) (Figure 4A). Specif-ically, vSMC contractile markers such as myocardin, calponin,
SM22a, and smoothmusclemyosin heavy chain (Myh11) are upre-
gulated, whereas in proliferating/synthetic vSMC, these markers
are generally decreased (Owens et al., 2004). Given the prominent
role of pericytes in angiogenic vessel remodeling (Hamzah et al.,
2008a; Song et al., 2005; Winkler et al., 2004; Xian et al., 2006),
we hypothesized that LIGHT may induce vessel normalization by
regulating pericyte contractile phenotype. Strikingly, CD31+ blood
vessels in LIGHT-RGR-treated tumors are coveredwith increased
numbers of myocardin-, caldesmon-, and calponin-positive cells
(Figures S4A–S4D); the vast majority of these cells co-localize
with NG2+/aSMA+ pericytes (Figures 4B–4D). Conversely,
collagen I, a marker for synthetic vSMC is downregulated (Figures
4E and S4E). Both, contractile marker expression and tumorcember 29, 2015 ª2015 The Authors 2691
Figure 4. LIGHT-RGR Treatment Induces
Contractile Properties in Intratumoral Peri-
cytes
(A) Comparative gene expression analysis of tumors
isolated from untreated 27-week-old RIP1-Tag5
mice and mice treated with 0.2 ng LIGHT-RGR for
2 weeks. Pericyte contractile and differentiation
markers were selected for qPCR analysis. Data are
shown as fold regulation in LIGHT-RGR tumors
compared to untreated controls, n = 3–6 mice, *p <
0.05, Student’s t test.
(B–E) RIP1-Tag5 mice (27 weeks old) were left un-
treated (Untr) or treated for 2 weeks with 0.2 ng
LIGHT-RGR (LR). (B) Myocardin co-localization with
NG2+ pericytes in controls and LR-treated groups
and quantification of myocardin induction. (C)
Caldesmon, (D) calponin, (E) collagen I (Col I) co-
localization with aSMA+ pericytes and quantifica-
tion. Representative images from three indepen-
dent experiments are shown. n = 5–10 mice, *p <
0.05, **p < 0.01, ***p < 0.0001, Student’s t test. Data
are presented as mean ± SD. Scale bars, 50 mm.
See also Figures S4 and S5.perfusion, increaseover time in direct correlationwith LIGHT-RGR
therapy (Figures S4F–S4H). These findings suggest that loss of
contractile properties in pericytes is part of the angiogenic switch
in RIP1-Tag5 tumors, and restoration of a contractile phenotype
normalizes the vascular bed. Importantly, LIGHT-RGR treatment
of orthotopically implanted breast tumors recapitulates key fea-
tures of LIGHT-RGR-treated insulinomas. This includes vascular
stabilizationandenhancedperfusion that in turn improvesoxygen-
ation of highly hypoxic breast cancers and also induces a down-
ward trend for lung metastases (p = 0.1, Figures S5A–S5E).2692 Cell Reports 13, 2687–2698, December 29, 2015 ª2015 The AuthorsPericyte Contractile Properties Are
Regulated by Macrophage-Derived
TGF-b
Having shown active pericyte remodeling
in vivo, we next sought to determine the
factor(s) involved in this process by using
a well-established model of undifferenti-
ated mesenchymal 10T1/2 cells (Hirschi
et al., 1998). Although 10T1/2 cells express
LTbR, LIGHT in itself does not induce upre-
gulation of contractile proteins (Figures
S6A and S6B), thus suggesting possible
indirect effects of LIGHT-RGR on pericyte
contractile phenotype in vivo. Interest-
ingly, macrophages that predominantly
express the LIGHT receptor HVEM (Fig-
ure S6C) increase in LIGHT-RGR-treated
tumors and also align more closely with
the tumor vasculature (Figures 5A and
5B). Moreover, as indicated by our gene
signature (Figure 4A), TGF-b is induced
around the remodeling vasculature and
almost exclusively co-localizes with peri-
vascular CD68+ macrophages following
LIGHT-RGR treatment (Figures 5C andS6D–S6F). TGF-b has been shown to mature mesenchymal pre-
cursor cells such as 10T1/2 into vSMC (Hirschi et al., 1998) (Fig-
ure S6G) consistent with TGF-b being a direct transcriptional
activator of SMC differentiation genes (Alexander and Owens,
2012). This prompted us to investigate the role of macrophages
in vessel differentiation. Indeed, tissue culture supernatant of
macrophages isolated ex vivo from LIGHT-RGR-treated tumors
induces contractile markers in 10T1/2 cells as exemplified by
myocardin and caldesmon staining. Simultaneous incubation
with macrophage-conditioned medium and TGF-b blocking
Figure 5. LIGHT-Activated Macrophages in the Peri-Vascular Niche
Secret TGF-b and Induce Pericyte Differentiation
(A) Histology image of CD68+ macrophages in untreated RIP1-Tag5 mice
(Untr), or mice treated for 2 weeks with 0.2 ng LIGHT-RGR (LR) and quantifi-
cation of intratumoral CD68+ signals. n = 4–5 mice, *p < 0.05, **p = 0.006,
Student’s t test. Scale bar, 100 mm.
(B) Images depict CD68+ macrophage location in relation to CD31+ vessels
and quantification of CD68/CD31 association as % total surface area. Arrows
point at direct overlay (yellow). n = 4–5 mice, *p < 0.05, **p = 0.006, Student’s
t test. Scale bar, 20 mm.
(C) Histology image of TGF-b+/CD68+ double-positivemacrophages in relation
to CD31+ vessels (arrows point at triple overlay, white). Quantification of
TGF-b+/CD68+ double positive macrophages (found exclusively around ves-
sels) as % overlay in relation to total TGF-b signals in both treatment groups.
n = 4–5 mice, *p < 0.05, **p = 0.006, Student’s t test. Scale bar, 20 mm.
(D and E) In vitro stimulation of 10T1/2 cells with conditioned medium (CM)
from macrophages isolated from untreated RIP1-Tag5 tumors (Ctrl MØ) or
tumors after 2 weeks of LIGHT-RGR treatment (LRMØ) induces (D) myocardin
Cell Repantibodies abolishes myocardin/caldesmon induction in vitro
(Figures 5D and 5E). In addition, in vivo treatment of tumor-
bearing RIP1-Tag5 mice with LIGHT-RGR and TGF-b-blocking
antibodies neutralizes LIGHT-RGR effects and impairs tumor
perfusion (Figure 5F). These results suggest that tumor-targeted
LIGHT induces macrophages to secrete TGF-b that, in turn, ac-
tivates contractile properties in pericytes. LIGHT-induced ef-
fects are remarkably specific and do not induce a general shift
in macrophage polarization (Figures S6H and S6I). Moreover,
potential TGF-b-mediated endothelial-mesenchymal transition
as assessed by phenotypic conversion of endothelial cells into
FSP-1+ fibroblast-like cells (Zeisberg et al., 2007) or loss of endo-
thelial cell contact integrity (Krizbai et al., 2015) were not
observed consistent with absence of local invasion or increased
distant metastases (Figures S6J and S6K).
To further assess the critical role ofmacrophages in vivo, perito-
neal macrophages from syngeneic donor mice were isolated and
stimulated with LIGHT overnight. Consistent with our in vivo data,
LIGHT induces peritoneal macrophages to secrete TGFb (Fig-
ure 6A). Ex vivo-stimulated macrophages (CD11b+) were adop-
tively transferred into tumor-bearing RIP1-Tag5 mice (Figure 6B).
Both, control and LIGHT-treatedmacrophages, home into tumors
and form clusters within the tumor stroma (Figures S7A and S7B).
Remarkably, only ex vivo LIGHT-stimulated, TGF-b-secreting
peritoneal macrophages recapitulate LIGHT-RGR treatment by
reducing hemorrhaging and restoring vessel functionality; in
contrast, control macrophages do not change tumor appearance
or perfusion. Furthermore, transfer of LIGHT-stimulated macro-
phages with simultaneous injection of TGF-b-blocking antibodies
abolishes improved vessel functionality (Figures 6C–6E). Overall,
these experiments demonstrate the crucial role of TGF-
b-secretingmacrophages in LIGHT-inducedvessel normalization.
Rho Kinase Signaling Is Crucial for TGF-b-Induced
Vessel Normalization
To further elucidate the mechanism of TGF-b-induced vSMC dif-
ferentiation, Rho kinase-dependent signalingwas assessed. Inter-
estingly, the phosphorylated form of the Rho kinase downstream
effector myosin light-chain (MLC) is significantly upregulated
around vessels under treatment. Indeed, pMLC strongly co-local-
izes with peri-endothelial pericytes from LIGHT-RGR-treated but
not control tumors (Figure 7A). Thus, TGF-b-inducedpericyte con-
tractile phenotype may be Rho kinase-dependent. In vitro
blockade of Rho kinase during incubation of 10T1/2 cells with
macrophage conditioned medium abolishes myocardin expres-
sion similar to TGF-b-blocking antibodies (Figure 7B). Importantly,
simultaneous treatment of RIP1-Tag5 mice with LIGHT-RGR
and Rho kinase inhibitor in vivo decreases tumor perfusion inand (E) caldesmon expression that is inhibited by TGF-b-blocking antibodies
(TGF-b block); n = 10–11. Representative images from three independent
experiments are shown. **p < 0.001, Student’s t test. Scale bars, 50 mm.
(F) Mice were treated with four injections of LR and TGF-b-blocking antibodies
(TGF-b block) for 2 weeks followed by assessment of tumor perfusion with
FITC-lectin. Quantification of perfused vessels (yellow) (n = 3–7). *p = 0.01, LR
versus untreated; **p < 0.0001, LR versus LR + TGF-b block; Student’s t test.
Scale bar, 100 mm. Data are presented as mean ± SD.
See also Figure S6.
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Figure 6. Adoptive Transfer of LIGHT-Acti-
vated Macrophages Mimics LIGHT-RGR
Treatment
(A) Quantification of TGF-b secreted by ex vivo
LIGHT-stimulated peritoneal macrophages, n = 3,
*p < 0.05, Student’s t test.
(B) Schematic outline of adoptive transfer of perito-
neal macrophages into tumor-bearing RIP1-Tag5
mice.
(C) Macroscopic appearance of control tumors (AdT
PBS MØ), tumors after adoptive transfer of LIGHT-
stimulatedmacrophages (AdT LIGHTMØ), or tumors
after adoptive transfer of LIGHT-stimulated macro-
phages with TGF-b-blocking antibodies (AdT LIGHT
MØ + TGF-b block). Dotted circles indicate tumors
that are embedded in exocrine pancreatic tissue.
(D) Overlay of CD31+ vessels with FITC-lectin de-
lineates perfused (yellow) and non-perfused (red)
tumor vessels after adoptive transfers (AdT) of peri-
toneal macrophages stimulated with PBS (AdT PBS
MØ), LIGHT without (AdT LIGHT MØ) or with TGF-
b-blocking antibodies (AdT LIGHT MØ + TGF-b
block) into RIP1-Tag5 mice. Scale bar, 100 mm.
(E) Quantification of ratio lectin/CD31 in all groups;
n = 3 mice. **p < 0.001, ***p < 0.0001, Student’s
t test. Data are presented as mean ± SD.
See also Figure S7.LIGHT-RGR-treated animals to untreated control levels (Fig-
ure 7C). Collectively, these data demonstrate that targeting low
doses of LIGHT into tumors triggers TGF-b secretion by resident
macrophages; this in turn induces pericyte differentiation and nor-
malizes tumor vessels in a Rho kinase-dependent manner.
DISCUSSION
To exploit the inherent plasticity of stromal cells as adjuvant can-
cer therapy is an attractive concept (Coussens et al., 2013;
Johansson et al., 2014). Here, we developed a strategy to specif-
ically deliver LIGHT into solid tumors and uncovered its potential2694 Cell Reports 13, 2687–2698, December 29, 2015 ª2015 The Authorsto normalize vessels by inducing pericyte
differentiation. Smooth muscle cell pheno-
typic switching is an integral part of embry-
onic development and wound healing. For
instance, during vascular injury, vSMC de-
differentiate and increase proliferation,
migration, andmatrix synthesis; upon reso-
lution of the insult a differentiated, contrac-
tile state is reinstalled (Owens et al., 2004).
Pericytes share many features of vSMC but
so far little is known about their contractile
phenotype in tumors.
Blood vessels in RIP1-Tag5 tumors are
highly angiogenic, lack contractile
markers, and tumors are notoriously diffi-
cult to treat. As documented here, low
dose LIGHT-RGR treatment normalizes
tumor vessels in a pericyte-dependent
process that in turn reduces hemorrhag-ing, increases tumor perfusion, and efficacy of chemo- and
immunotherapy. Similar effects are observed in orthotopic
breast cancer where LIGHT-RGR significantly reduces tumor
hypoxia. Pericyte-mediated vascular normalization has previ-
ously been shown to enhance the effectiveness of adoptive
immunotherapy (Hamzah et al., 2008a; Huang et al., 2013;
Shrimali et al., 2010), possibly by reducing intratumoral pres-
sure or alleviating hypoxia. Alternatively, active pericyte-leuko-
cyte interactions may facilitate the transmigration process.
Recently, it has been shown in models of venous inflammation
that pericytes are capable of orchestrating leukocyte migration
(Proebstl et al., 2012; Stark et al., 2013; Wang et al., 2012).
Figure 7. Rho Kinase Signaling Is Crucially
Involved in LIGHT-RGR-Induced Vascular
Normalization
(A) Co-localization of phosphoMLC+ cells (pMLC)
with aSMA+ pericytes in RIP1-Tag5 mice treated
with LIGHT or LIGHT-RGR (LR) for 2 weeks;
quantification of pMLC-positive pericytes, n = 3–5.
*p < 0.05, Student’s t test. Scale bar, 50 mm.
(B) Representative images of myocardin staining in
10T1/2 cells after in vitro stimulation with condi-
tioned media from LIGHT-RGR-treated tumor
macrophages in the absence (LR MØ CM) or in the
presence of Rho kinase inhibitor (LR MØ CM +
Y27632). Quantification of myocardin induction in
all experimental groups, n = 5–15, ***p % 0.0001,
Student’s t test. Scale bars, 50 mm.
(C) Simultaneous treatment of RIP1-Tag5micewith
LIGHT-RGR and Rho kinase inhibitor (LR + Fasudil)
or Fasudil alone for 2 weeks and assessment of
ratio FITC-lectin/CD31 as surrogate marker for tu-
mor perfusion, n = 3 mice, **p % 0.001 compared
to all experimental groups, Student’s t test. Values
from control and LR-treated tumors (dashed lines)
are shown as reference only (original data shown in
Figure 3B). Data are presented as mean ± SD.Common underlying themes in these inflammatory models are
changes in pericyte shape/cytoskeleton and basement mem-
brane re-organization (Proebstl et al., 2012; Wang et al.,
2012). Intriguingly, LIGHT-induced vessel normalization also
correlates with strong induction of pericyte contractile markers
and changes in basement membrane, consistent with active
phenotypic remodeling. Pericytes control proliferation of capil-
lary endothelial cells in a cell contact-dependent manner
in vitro (Durham et al., 2014; Kutcher et al., 2007). Therefore,
it is conceivable that loss of contractile properties in intratu-
moral pericytes is an integral part of excessive vessel growth
and tumor angiogenesis; reversing this process may in turn
induce normalization of the entire vascular bed.
Interestingly, pericyte contractile phenotype is most likely not
induced by LIGHT itself, but by TGF-b secreted by LIGHT-stim-
ulated peri-vascular cells, predominantly macrophages. Indeed,
minute amounts of LIGHT trigger significant TGF-b production
exclusively in the peri-vascular niche, demonstrating substantial
amplification to locally effect normalization.
TGF-b is a well-known differentiation factor for mural precur-
sors such as 10T1/2 cells (Hirschi et al., 1998). In cancer,
TGF-b can suppress or promote angiogenesis, depending on
the context (Liu et al., 2012; Pardali and ten Dijke, 2009; Sounni
et al., 2010). In our study, TGF-b is exclusively secreted by peri-Cell Reports 13, 2687–2698, Devascular cells and thus acts at short range
to restore vascular stability but not endo-
thelial to mesenchymal transition; this is
in clear contrast to widespread TGF-
b-induced fibrosis of activated tumor-
associated fibroblasts that can promote
tumorigenesis and metastatic dissemina-
tion (Massague´, 2008). The exquisite role
of peri-vascular macrophages in ampli-fying LIGHT signals highlights their own plasticity and potential
to remodel the tumor environment including angiogenic vessels
for improved anti-tumor effects (De Palma and Lewis, 2013; Jo-
hansson et al., 2012b). There is precedence for a LIGHT-TGF-b
signaling axis in inflammatory disease such as asthma. There,
LIGHT enhances pathological tissue remodeling that involves
upregulation of TGF-b, potentially as a result of LIGHT-LTRb in-
teractions with macrophages (Doherty et al., 2011).
Expression of vSMC differentiation markers is regulated by
several pathways including RhoA/Rho kinase signaling. Rho ki-
nase plays a crucial role in TGF-b-induced vSMC contractility
since it controls both cytoskeletal activity and transcription of
contractile genes (Althoff et al., 2012; Mack, 2011). Indeed, peri-
cyte contractile properties and remodeling of the vascular bed in
response to LIGHT is RhoA/Rho kinase-dependent. This is
consistent with in vitro data demonstrating that TGF-b and Rho
kinase signaling can control the contractile phenotype of peri-
cytes (Kutcher et al., 2007; Sieczkiewicz and Herman, 2003). In
contrast to abnormal Rho-mediated sensing of mechanical
cues in the tumor microenvironment (Sanz-Moreno et al.,
2011), we demonstrate here that restoring local Rho kinase
activity in pericytes reduces vascular leakiness and angiogenic
activity; a beneficial effect of Rho kinase signaling has also
been observed in tumor endothelial cells (Mavria et al., 2006).cember 29, 2015 ª2015 The Authors 2695
Pericytes are important regulators of tumor vessel function
and loss of pericytes or impaired TGF-b signaling in angiogenic
vessels is associated with metastasis (Anderberg et al., 2013;
Cooke et al., 2012; Xian et al., 2006). However, pericyte contrac-
tile markers in cancer have been largely unexplored even though
there is clinical evidence that reduction of vessel contractile pro-
teins is a prognostic marker for metastasis. For instance, ex-
pression of caldesmon and calponin in intratumoral vSMC of
malignant melanoma with metastatic potential is reduced
compared to benign melanocytic tumors or normal tissue (Koga-
nehira et al., 2003). Moreover, calponin-deficiency in mice en-
hances metastatic spread implying that loss of vSMC-specific
contractile proteins changes vascular integrity (Taniguchi et al.,
2001). Furthermore, four vSMC-specific genes, including calpo-
nin, are downregulated in a 17-gene signature associated with
metastases of various human tumors. Conversely, components
of the extracellular matrix such as collagen type I are upregulated
(Ramaswamy et al., 2003) highlighting a causal role of vSMC
dysfunction in tumor progression. Thus, as shown here, the abil-
ity to regulate peri-endothelial pericyte contractile phenotype by
direct and locally-restricted targeting may have profound effects
on delivery of therapeutics, response to therapy and metastatic
dissemination and therefore warrants clinical evaluation.
EXPERIMENTAL PROCEDURES
For more details regarding the materials and methods used in this work, see
the Supplemental Experimental Procedures.
Mice and Cell Lines
RIP1-Tag5 transgenic mice were bred on a C3HeBFe background (Johansson
et al., 2012a). For adoptive transfers, mice transgenic for a Tag-specific T cell
receptor (TCR), restricted to H-2Kk (referred to as TagTCR8) (Geiger et al.,
1992) were used. All mice were kept under specific pathogen-free conditions
at the University of Western Australia. All experimental protocols were
approved by the Animal Ethics Committee of the University of Western
Australia. The murine mesenchymal cell line C3H10T1/2 (10T1/2) and murine
breast cancer cells (4T1) were purchased from the American Type Culture
Collection (ATCC).
Recombinant LIGHT/LIGHT-RGR
Mature murine LIGHT (with or without C-terminal RGR peptide (CRGRRSTG,
connected via a GGG linker) (Joyce et al., 2003) were cloned into Xho/BamH1
sides of the vector pET-44a (Novagen) to express soluble fusion proteins with
N-terminal Nus3 Tag/His3 Tag and purified, see Supplemental Experimental
Procedures.
Animal Studies
RIP1-Tag5 mice were subjected to short- or long-term treatment regimens.
Short-term treatment was initiated at 26–27 weeks of age for 2 weeks. Mice
were bi-weekly i.v. injected with 0.2 ng LIGHT or LIGHT-RGR in 100 ml PBS
(6 ng/kg). In some experiments TGF-b-blocking antibodies (1D11.16.8,
BioXCell) were co-injected with LIGHT-RGR. At 28–29 weeks of age, mice
were sacrificed and tumors were isolated for histology, RNA, or fluores-
cence-activated cell sorting (FACS) analysis. Long-term treatment in RIP1-
Tag5 mice was started at 22–23 weeks of age with bi-weekly i.v. injections
of LIGHTor LIGHT-RGRwith or without cyclophosphamide, adoptive transfers
of activated TagTCR8 T cells, or anti-Tag vaccine. Inhibition of Rho kinase
in vivo was performed in short-term experiments with fasudil hydrochloride
(LKT Laboratories) administered at 30 mg/kg, 10 min prior to LIGHT-RGR in-
jections. For adoptive transfers of macrophages, 4% thioglycolate-induced
peritoneal macrophages were harvested, washed, seeded, and stimulated
with LIGHT or PBS. Six hours after stimulation, macrophages were detached,2696 Cell Reports 13, 2687–2698, December 29, 2015 ª2015 The Aucounted, and resuspended in PBS. Cells (2 3 106) were intraperitoneally (i.p.)
injected into tumor-bearing RIP1-Tag5 mice with or without TGF-b-blocking
antibodies as published (Klug et al., 2013). Mice were analyzed 4 days later,
see Supplemental Experimental Procedures.
Statistical Analyses
Student’s t test was used to distinguish differences between groups. To eval-
uate therapeutic efficacy based on categorical data, a 23 2 contingency table
with survival recorded at end point (30 weeks) was used. The odds ratio was
calculated by dividing the numbers of mice alive/dead in the LR + AdT group
(11/4) and numbers of mice alive/dead in the AdT group (4/8). To assess sig-
nificance of survival at 30 weeks, Fisher’s exact test and Pearson’s chi-square
test were employed. A p value% 0.05 was considered statistically significant.
Error bars indicate SD.
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org/10.1016/j.celrep.2015.12.004.
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